GlassScriptPhysician profile
Jeffrey D Floyd
NPI 1629002761
$8,963.65
in general payments reported to CMS, 2019-2025
63 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $804 · 2021: $1,184 · 2022: $1,437 · 2023: $1,477 · 2024: $1,737 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,708 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,708.41 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $950.36 | 2021-2025 | |
| Novo Nordisk INC | $724.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $639.00 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $621.17 | 2019-2025 | Otezla, Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $496.65 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Pfizer INC. | $407.16 | 2019-2025 | |
| Lilly USA, LLC | $396.39 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $384.54 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.79 | 2020-2024 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.21 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $281.77 | 2020-2025 | Trintellix |
| Ibsa Pharma INC. | $249.49 | 2020-2025 | Tirosint, Licart, Flector |
| Mannkind Corporation | $232.89 | 2020-2023 | Afrezza |
| Amarin Pharma, INC. | $211.52 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $194.57 | 2021-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.